Boston, Massachusetts, United States
Contact Info
1K followers
500+ connections
Activity
-
NT-0796: A Clinical CNS-Active NLRP3 Inhibitor Prodrug with Anti-Neuroinflammatory Activity | https://lnkd.in/d85vEhpi NT-0796, developed by…
NT-0796: A Clinical CNS-Active NLRP3 Inhibitor Prodrug with Anti-Neuroinflammatory Activity | https://lnkd.in/d85vEhpi NT-0796, developed by…
Liked by Noelle Hutchins, PhD
-
What makes our Phase 2 drug candidate NT-0796 unique amongst NLRP3 inflammasome inhibitors? It contains an ester delivery vehicle, designed to allow…
What makes our Phase 2 drug candidate NT-0796 unique amongst NLRP3 inflammasome inhibitors? It contains an ester delivery vehicle, designed to allow…
Liked by Noelle Hutchins, PhD
Experience & Education
Publications
-
Real-time resolution of point mutations that cause phenovariance in mice.
Proceedings of the National Academy of Sciences of the United States of America
With the wide availability of massively parallel sequencing technologies, genetic mapping has become the rate limiting step in mammalian forward genetics. Here we introduce a method for real-time identification of N-ethyl-N-nitrosourea-induced mutations that cause phenotypes in mice. All mutations are identified by whole exome G1 progenitor sequencing and their zygosity is established in G2/G3 mice before phenotypic assessment. Quantitative and qualitative traits, including lethal effects, in…
With the wide availability of massively parallel sequencing technologies, genetic mapping has become the rate limiting step in mammalian forward genetics. Here we introduce a method for real-time identification of N-ethyl-N-nitrosourea-induced mutations that cause phenotypes in mice. All mutations are identified by whole exome G1 progenitor sequencing and their zygosity is established in G2/G3 mice before phenotypic assessment. Quantitative and qualitative traits, including lethal effects, in single or multiple combined pedigrees are then analyzed with Linkage Analyzer, a software program that detects significant linkage between individual mutations and aberrant phenotypic scores and presents processed data as Manhattan plots. As multiple alleles of genes are acquired through mutagenesis, pooled "superpedigrees" are created to analyze the effects. Our method is distinguished from conventional forward genetic methods because it permits (1) unbiased declaration of mappable phenotypes, including those that are incompletely penetrant (2), automated identification of causative mutations concurrent with phenotypic screening, without the need to outcross mutant mice to another strain and backcross them, and (3) exclusion of genes not involved in phenotypes of interest. We validated our approach and Linkage Analyzer for the identification of 47 mutations in 45 previously known genes causative for adaptive immune phenotypes; our analysis also implicated 474 genes not previously associated with immune function. The method described here permits forward genetic analysis in mice, limited only by the rates of mutant production and screening.
-
The New Normal: Immmunomodulatory Agents Aganst Sepsis Immune Suppression
Trends Molecular Medicine/ELSEVIER
-
Kupffer Cells Protect Liver Sinusoidal Endothelial Cells from Fas-Dependent Apoptosis in Sepsis by Down-Regulating gp130
American Journal of Pathology/ELSEVIER
Organizations
-
Society of Leukocyte Biology
-
More activity by Noelle
-
#NEWS – SR One congratulates #portfoliocompany Dren Bio, Inc. on their new strategic collaboration agreement with Novartis. Given Dren Bio’s robust…
#NEWS – SR One congratulates #portfoliocompany Dren Bio, Inc. on their new strategic collaboration agreement with Novartis. Given Dren Bio’s robust…
Liked by Noelle Hutchins, PhD
-
Hummingbird Bioscience announces key leadership appointments. Kon Yew Kwek, BMBCh, DPhil is promoted to Chief Medical Officer, from Senior Vice…
Hummingbird Bioscience announces key leadership appointments. Kon Yew Kwek, BMBCh, DPhil is promoted to Chief Medical Officer, from Senior Vice…
Liked by Noelle Hutchins, PhD
-
Very proud of our awesome BD team for securing this exciting opportunity on behalf of the Immunology TA!
Very proud of our awesome BD team for securing this exciting opportunity on behalf of the Immunology TA!
Liked by Noelle Hutchins, PhD
-
Patients with mild Alzheimer’s disease who received an older Novo Nordisk GLP-1 drug experienced a slower rate of cognitive decline than their peers…
Patients with mild Alzheimer’s disease who received an older Novo Nordisk GLP-1 drug experienced a slower rate of cognitive decline than their peers…
Liked by Noelle Hutchins, PhD
-
Hi all, as you probably have heard, Escient was acquired by Incyte in May 2024. We couldn't have put 2 First-in-class compounds in Phase II (for…
Hi all, as you probably have heard, Escient was acquired by Incyte in May 2024. We couldn't have put 2 First-in-class compounds in Phase II (for…
Liked by Noelle Hutchins, PhD
-
BREAKING: The #FDA has approved Guardant Shield, a blood test to detect cancer in the colon or rectum. #CRCSM https://lnkd.in/eF76F2XH
BREAKING: The #FDA has approved Guardant Shield, a blood test to detect cancer in the colon or rectum. #CRCSM https://lnkd.in/eF76F2XH
Liked by Noelle Hutchins, PhD
-
Now published online, these data are the first look at aficamten in non-obstructive HCM over a 36 week treatment period in the FOREST-HCM open-label…
Now published online, these data are the first look at aficamten in non-obstructive HCM over a 36 week treatment period in the FOREST-HCM open-label…
Liked by Noelle Hutchins, PhD
-
Please join CTI Life Sciences Fund in welcoming Ron Cooper as the CEO of enGene, a CTI portfolio company. We are excited to have Mr. Cooper leading…
Please join CTI Life Sciences Fund in welcoming Ron Cooper as the CEO of enGene, a CTI portfolio company. We are excited to have Mr. Cooper leading…
Liked by Noelle Hutchins, PhD
-
Under the deal announced Monday with the California biotech, German pharma Boehringer Ingelheim is gaining access to novel immune checkpoint…
Under the deal announced Monday with the California biotech, German pharma Boehringer Ingelheim is gaining access to novel immune checkpoint…
Liked by Noelle Hutchins, PhD
-
BioAge is pleased to announce the initiation of the STRIDES Phase 2 clinical trial evaluating azelaprag, an oral exercise mimetic, for the treatment…
BioAge is pleased to announce the initiation of the STRIDES Phase 2 clinical trial evaluating azelaprag, an oral exercise mimetic, for the treatment…
Liked by Noelle Hutchins, PhD
-
BGV (BioGeneration Ventures) portfolio company Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting…
BGV (BioGeneration Ventures) portfolio company Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting…
Liked by Noelle Hutchins, PhD
-
Encouraged by the potential of the weight-loss candidates acquired from Carmot Therapeutics, Inc., Roche will speed up the development of its obesity…
Encouraged by the potential of the weight-loss candidates acquired from Carmot Therapeutics, Inc., Roche will speed up the development of its obesity…
Liked by Noelle Hutchins, PhD
-
The GLP-1 era in medicine is just getting started https://lnkd.in/gagmrVri
The GLP-1 era in medicine is just getting started https://lnkd.in/gagmrVri
Liked by Noelle Hutchins, PhD
Other similar profiles
-
Alex Loftis
Senior Associate at Vida Ventures
Connect -
Marla Jalbut, MD, MBA
Connect -
Benjamin Youn, PhD, MBA
Investment Associate, Omega Funds
Connect -
Lauren Mifflin
Connect -
Travis Hughes MD, PhD, MPH
Digitalis Ventures - Life Sciences Investment Team
Connect -
Aniqa Tasnim
Associate at 5AM Ventures
Connect -
Alim Ladha
Connect -
Linda T. Vo, PhD
Connect -
Rebecca Silberman
Connect -
Suan Tuang, M.D., Ph.D.
Connect
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More